Featured Story | By Annalee Armstrong,James Waldron Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million). read more |
| |
|---|
|
Top Stories By Nick Paul Taylor One year after Intellia’s landmark data, Novartis is making a play for the in vivo gene editing market. The move sees the Swiss pharma pay Precision BioSciences $75 million upfront, with up to $1.4 billion in milestones, to secure rights to a potential treatment for sickle cell disease and beta thalassemia. read more By Gabrielle Masson Gene editing giant CRISPR Therapeutics is moving away from multiple myeloma candidate CTX120, while a small, separate dataset released yesterday sent the company’s stock plummeting. read more By Kevin Dunleavy Visiting Washington, D.C., last week, Axcella CEO Bill Hinshaw is trying to enlist congressional allies to help with long COVID. He’s the first to admit that it’s not an easy sell. read more By James Waldron Novartis has invested another $17.7 million as part of a 10-year plan to address racial inequalities in clinical trials. The Swiss pharma and its U.S. foundation set up the Beacon of Hope initiative in July 2021 in collaboration with 26 historically Black colleges, universities and medical schools. read more By James Waldron Alladapt Immunotherapeutics has refilled the bank balance with $119 million in institutional financing from the likes of Novartis, which will be used to follow the biotech's dream of developing the first FDA-approved therapy to treat the majority of food allergy patients. read more By Gareth Macdonald Cancer patients from diverse backgrounds are finding empowerment in taking charge of their care as interest in clinical trial participation grows, according to TrialJectory. read more By Kevin Dunleavy The FDA has blessed Merck's pneumococcal vaccine Vaxneuvance for children ages 6 weeks to 17 years, giving the company a running start on its next generation pneumococcal vaccine race with Pfizer. read more By Natalie Missakian Patient groups may view pharma more favorably thanks to its work during the pandemic, but HIV and AIDS patients groups are a tougher sell, according to a new survey. read more By Paige Minemyer LAS VEGAS—Stemming the tide of rising drug prices will require bringing all the major players to the table, experts said Tuesday. read more Resources Sponsored by: Blue Matter, strategic consultants in the life sciences Medical Affairs plays a critical role in generating insights to inform strategic decisions, but that role is changing. This paper explores why, and how MA teams can stay ahead of the curve. Sponsored by: PwC Don’t miss these critical considerations when evaluating your HCP interactions management program. Sponsored By: Thermo Fisher Scientific Sponsored by Thermo Fisher Scientific The journey for starting or expanding a lab can be exhilarating, while also being challenging--learn how this free program provides savings and solutions to support your goals. Sponsored By: CG Life Explore the new cell therapy handbook from Thermo Fisher Scientific. Sponsored by: Merit Solutions Quality operations guide your organization through regulatory compliance processes and safeguard your products, processes, and reputation. But your team is capable of so much more. Quality incident data and processes can be a driver of significant business value if shared with other stakeholders. Sponsored by: Catalent Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored by: Catalent What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? | 
